News
Phase Advance and QNova Capital Forge Alliance to Usher in AI-Driven, Non-Animal Drug Development Era
Published October 16, 2025
OrganTech Inc. Partners with U.S. Company for FDA Application of Next-Generation Bio-Implant
Published August 26, 2025
QNova LifeSciences & Liberi Group Enter Exclusive Consultancy Agreement
Published May 13, 2025
CSSi LifeSciences is Now QNova LifeSciences
Published January 13, 2025
Trifermed and CSSi LifeSciences Join Forces to Accelerate Global Healthcare Innovation Access into the U.S. Market
Published November 26, 2024
Gaining Market Access with New MedTech Innovations: CSSi LifeSciences Partners with Market Strategy Leader, Jaunt
Published April 18, 2024
CSSi LifeSciences Announces Strategic Partnership with Australian States to Facilitate Entry into the US Healthcare Market
Published December 6, 2023
These Four Leading CROs in Maryland are Driving Success in Life Sciences
Published June 8, 2023
Biotoxtech and CSSi LifeSciences Strengthen Business Cooperation for New Drug Development
Published April 19, 2023
SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation
Published October 12, 2022
BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Announces Presentation at ACRO Summit 2022 on Sensitizing Head and Neck Cancer to Radiation Using the Company’s Cerium Oxide Nanoparticles | Business Wire
Published March 10, 2021
Tonic Bioventures and CSSi LifeSciences Enter Partnership to Form A New Life Sciences Fund
Published January 6, 2021
Tonic Bioventures and CSSi LifeSciences Enter Partnership to Form A New Life Sciences Fund
Published January 6, 2021
Ernesto P. Chanona, Ph.D. Joins CSSi LifeSciences As Director of Business Development
Published January 5, 2021